1. Generics Bulletin
  2. >>Leadership

Biocon Biologics Builds Out Management Team

Names COO, Development Chief, BD Head, And Communications & Branding Lead

 
• By Dave Wallace

As it continues to build on the biosimilars business gained from a major transaction with former partner Viatris, Biocon Biologics has announced a raft of executive appointments to bolster its management team.

Linked hexagonal blocks with person icons, representing connections in a management team
Biocon Biologics has announced several key leadership appointments • Source: Shutterstock

Biocon Biologics has announced multiple new additions to its management team, as it continues to transform in the wake of a major $3bn deal that last year saw it take over the global biosimilars business of former partner Viatris.

The Biocon subsidiary – which has since late 2022 been led by Shreehas Tambe as CEO (Also see "Tambe Moves Up To Lead Biocon Biologics" - Generics Bulletin, 6 December, 2022

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.